Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation.
Damage to axons is taken as a key factor of disability in multiple sclerosis, but its pathogenesis is largely unknown. Axonal injury is believed to occur as a consequence of demyelination and was recently shown to be a feature even of the early disease stages. The present study was aimed at characterizing the association of axonal injury and histopathological hallmarks of multiple sclerosis such as demyelination, cellular infiltration and expression of inflammatory mediators. Therefore, axon reduction and signs of acute axonal damage were quantified in early lesion development of chronic multiple sclerosis and correlated with demyelinating activity and inflammation. Patients with secondary progressive multiple sclerosis revealed the most pronounced axonal injury, whereas primary progressive multiple sclerosis patients surprisingly showed relatively little acute axonal injury. Acute axonal damage, as defined by the accumulation of amyloid precursor protein (APP), was found to occur not only in active demyelinating but also in remyelinating and inactive demyelinated lesions with a large inter-individual variability. Only few remyelinating lesions were adjacent to areas of active demyelination. In this minority of lesions, axonal damage may have originated from the neighbourhood. APP expression in damaged axons correlated with the number of macrophages and CD8-positive T lymphocytes within the lesions, but not with the expression of tumour necrosis factor-alpha (TNF-alpha) or inducible nitric oxide synthase (iNOS). Axonal injury is therefore, at least in part, independent of demyelinating activity, and its pathogenesis may be different from demyelination. This has major implications for therapeutic strategies, which aim at preventing both demyelination and axonal loss.
Bitsch
A
A
Department of Neurology, Georg-August-Universität, Göttingen, Germany.
Schuchardt
J
J
Bunkowski
S
S
Kuhlmann
T
T
Brück
W
W
D000293:Adolescent; D000328:Adult; D016564:Amyloid beta-Protein Precursor / Q000032:analysis; D001369:Axons / Q000737:chemistry / Q000276:immunology* / Q000473:pathology*; D001706:Biopsy; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002648:Child; D003711:Demyelinating Diseases / Q000473:pathology*; D005260:Female; D015870:Gene Expression / Q000276:immunology; D006801:Humans; D018836:Inflammation Mediators / Q000276:immunology; D008264:Macrophages / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000276:immunology* / Q000473:pathology*; D009186:Myelin Sheath / Q000276:immunology / Q000473:pathology; D009443:Neuritis / Q000276:immunology / Q000473:pathology*; D019001:Nitric Oxide Synthase / Q000235:genetics / Q000276:immunology; D052247:Nitric Oxide Synthase Type II; D012333:RNA, Messenger / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000276:immunology
D016564:Amyloid beta-Protein Precursor; D018836:Inflammation Mediators; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; C496319:NOS2 protein, human; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II